Multiple sclerosis (MS) is a condition with extensive infiltration of leukocytes into the central nervous system (CNS) and the activation of CNS-intrinsic microglia. The neuroinflammation in MS is accompanied by the loss of oligodendrocytes and myelin, prominent injury to axons, and the death of neurons. We will refer to the collective loss of neural elements and cells herein as neurodegeneration. Much attention has been focused on the mechanisms and prevention of neurodegeneration, since it drives the progression of disability in MS. The initiating cause(s) of neurodegeneration in MS continues to be debated, with one school postulating an early role of dysfunction within the CNS that may not even be inflammatory; examples of such "inside-out" 1 initiators include mitochondrial dysfunction within axons, energy insufficiency, glutamate excitotoxicity, and dysfunctional organelles. In contrast, the opposing view ("outside-in") proposes abnormalities in immune processes outside the CNS that lead to the substantial entry of activated leukocytes into the CNS. Regardless of the initiating event, and it may be either in different MS individuals, the consequence is the over-representation of activated leukocytes and microglia within the CNS.
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While it must be emphasized that there are beneficial aspects of inflammatory processes that attempt defense and repair of the CNS, the extensive neuroinflammation in persons with MS cannot be favorable for CNS well-being. Indeed, markers of axonal injury and transection highly correlate with the density of immune cells in histological MS lesions, even in progressive MS. 2 Simultaneous magnetic resonance-positron emission tomography imaging with the 11 C-PBR28 tracer to detect an 18-kDa translocator protein present on activated microglia/macrophages in living MS subjects shows high correlation between activated immune cells, neurological disability, and impaired cognitive performance. 3 These associations are lent pathologic significance by studies in culture where products of activated T and B lymphocytes, and of macrophages and microglia, directly mediate neuronal and/or oligodendrocyte death. [4] [5] [6] Mechanisms of neurotoxicity mediated by immune cells include cell-associated Fas/FasL and the elaboration of factors such as free radicals, glutamate, proteases, granzyme B, and certain cytokines.
Thus, as inflammatory insults are major drivers of neural injury in MS, then stopping inflammation should slow or stop neurodegeneration in the condition. This therapeutic possibility is made more compelling by the result in the experimental autoimmune encephalomyelitis (EAE) inflammatory model of MS and in MS specimens, where mitochondrial and axonal injury caused by macrophages/microglia are not only protectable but also reversible. 7 In EAE experiments, many drugs that stop peripheral immune activity do not produce clinical signs or histopathology of MS if administered early, and ongoing axonal injury in the spinal cord of severely afflicted mice may even be halted by adequate inhibition of microglia and macrophages. 6 Those that argue that abrogating neuroinflammation does not stop neurodegeneration would provide the evidence that intense immunosuppression by potent disease-modifying therapies (DMTs) or incurred during hematopoietic stem cell transplants 8 do not slow axonal injury, brain atrophy, or progression of disability in MS. Moreover, they posit that most DMTs have no impact on progressive MS. Here, it must be pointed out that even at clinically isolated syndrome (CIS) of the first possible future presentation of MS, significant brain atrophy detected by magnetic resonance imaging (MRI) 9 has already occurred and many axons are already in the process of degenerating. Thus, the DMTs are placed in the unfavorable position of mitigating an ongoing and overt neurodegeneration, and their outcomes at best would be to prevent new insults from occurring, halt or reverse subtle degenerative changes, and slow the progression of disability.
To improve the odds of halting neurodegeneration by stopping inflammation, the diagnosis of MS must be made very early, certainly before CIS and perhaps even
Stop inflammation and you stop neurodegeneration in MS -YES
T Kalincik before radiologically isolated syndrome (a lesion at incidental MRI in a person who otherwise has no hints of MS) that precedes CIS in some subjects. Clearly, the capacity to diagnose MS very early is a new challenge for the MS field, but one with the potential to stop neurodegeneration by early institution of DMTs. Welltolerated medications with immune-modulating effects, such as the repurposed generic medication minocycline 10 or even high-dose vitamin D, could then be initiated promptly to deflect the impact of neuroinflammation on neurodegeneration. Importantly, these medications must enter the CNS to mitigate the injurious mechanisms caused by persistently activated microglia and infiltrated leukocytes directly.
If the neurodegenerative processes in MS originate from a non-immune insult within the CNS, such as dysfunction of organelles within oligodendrocytes, and if this underlying problem is not treated, then we submit that DMTs may not be able to counter such injury directly. Nonetheless, stopping inflammation can still mitigate the resultant neuroinflammation that enhances CNS injury, and this could lead to the substantial slowing of neurodegeneration.
On balance, we submit that since products of inflammation are potent drivers of axonal and myelin injury, and of oligodendrocyte and neuronal loss, stopping inflammation will slow if not stop neurodegeneration when the intervention is provided early in MS.
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